- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dellphi-304 Data Reinforce Role of Tarlatamab as Second-Line SOC in Small Cell Lung Cancer
June 3rd 2025, 12:24am
Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.
Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC
June 3rd 2025, 12:00am
Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.
Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma
June 2nd 2025, 11:02pm
Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.
Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression
June 2nd 2025, 10:33pm
Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.
Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer
June 2nd 2025, 10:24pm
Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.
COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC
June 2nd 2025, 9:35pm
COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.
D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma
June 2nd 2025, 8:40pm
D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.
Dr Duska on the Role of Immunotherapy With Definitive Treatment in High-Risk, Locally Advanced Cervical Cancer
June 2nd 2025, 8:32pm
Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.
Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels
June 2nd 2025, 8:25pm
The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.
Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer
June 2nd 2025, 8:07pm
Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.
Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer
June 2nd 2025, 7:39pm
Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.
Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer
June 2nd 2025, 7:33pm
Sarah Cannon Research Institute
Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.
EBC-129 Is Active and Safe in Heavily Pretreated mPDAC
June 2nd 2025, 7:25pm
EBC-129 monotherapy was active, generated responses, and had a manageable safety profile in heavily pretreated metastatic pancreatic ductal adenocarcinoma.
KEYNOTE-A18 Data Support Pembrolizumab Plus CCRT as New SOC in High-Risk Cervical Cancer
June 2nd 2025, 7:01pm
Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.
Perioperative Nivolumab Sustains EFS Advantage in Resectable NSCLC, With Enriched Benefit in ctDNA–, pCR Responders
June 2nd 2025, 6:52pm
Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.
Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer
June 2nd 2025, 6:19pm
Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.
Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC
June 2nd 2025, 4:39pm
Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.
LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC
June 2nd 2025, 4:02pm
The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.
Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer
June 2nd 2025, 4:00pm
Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.
Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC
June 2nd 2025, 3:20pm
Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.